These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 25963923)

  • 21. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
    Choi YJ; Rho JK; Jeon BS; Choi SJ; Park SC; Lee SS; Kim HR; Kim CH; Lee JC
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):381-8. PubMed ID: 19921194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.
    Shien K; Ueno T; Tsukuda K; Soh J; Suda K; Kubo T; Furukawa M; Muraoka T; Maki Y; Tanaka N; Yamamoto H; Kiura K; Mitsudomi T; Toyooka S; Miyoshi S
    Clin Lung Cancer; 2012 Nov; 13(6):488-93. PubMed ID: 22503506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells.
    Kim SM; Kim JS; Kim JH; Yun CO; Kim EM; Kim HK; Solca F; Choi SY; Cho BC
    Cancer Lett; 2010 Oct; 296(2):150-9. PubMed ID: 20444542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
    Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
    Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
    J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells.
    Jin HO; Hong SE; Kim CS; Park JA; Kim JH; Kim JY; Kim B; Chang YH; Hong SI; Hong YJ; Park IC; Lee JK
    Toxicol Appl Pharmacol; 2015 Aug; 287(1):17-25. PubMed ID: 25981168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
    Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
    Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
    Kobayashi N; Toyooka S; Soh J; Yamamoto H; Dote H; Kawasaki K; Otani H; Kubo T; Jida M; Ueno T; Ando M; Ogino A; Kiura K; Miyoshi S
    Lung Cancer; 2012 Feb; 75(2):161-6. PubMed ID: 21767894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC.
    Terai H; Soejima K; Yasuda H; Nakayama S; Hamamoto J; Arai D; Ishioka K; Ohgino K; Ikemura S; Sato T; Yoda S; Satomi R; Naoki K; Betsuyaku T
    Mol Cancer Res; 2013 Jul; 11(7):759-67. PubMed ID: 23536707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer.
    Wang YT; Pan SH; Tsai CF; Kuo TC; Hsu YL; Yen HY; Choong WK; Wu HY; Liao YC; Hong TM; Sung TY; Yang PC; Chen YJ
    Sci Rep; 2017 Mar; 7():44021. PubMed ID: 28290473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.
    Zhao BX; Wang J; Song B; Wei H; Lv WP; Tian LM; Li M; Lv S
    Mol Med Rep; 2015 Apr; 11(4):2767-74. PubMed ID: 25483995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
    Han SY; Zhao MB; Zhuang GB; Li PP
    Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
    Li XY; Wu JZ; Cao HX; Ma R; Wu JQ; Zhong YJ; Feng JF
    Oncol Rep; 2013 May; 29(5):1975-82. PubMed ID: 23440266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
    Koyama N; Uchida Y
    Anticancer Res; 2013 Nov; 33(11):5083-9. PubMed ID: 24222153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer.
    Wu Z; Doondeea JB; Gholami AM; Janning MC; Lemeer S; Kramer K; Eccles SA; Gollin SM; Grenman R; Walch A; Feller SM; Kuster B
    Mol Cell Proteomics; 2011 Dec; 10(12):M111.011635. PubMed ID: 21955398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphoproteome Profiling Reveals Molecular Mechanisms of Growth-Factor-Mediated Kinase Inhibitor Resistance in EGFR-Overexpressing Cancer Cells.
    Koch H; Wilhelm M; Ruprecht B; Beck S; Frejno M; Klaeger S; Kuster B
    J Proteome Res; 2016 Dec; 15(12):4490-4504. PubMed ID: 27794612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance.
    Torlot L; Jarzab A; Albert J; Pók-Udvari Á; Stahler A; Holch JW; Gerlinger M; Heinemann V; Klauschen F; Kirchner T; Kumbrink J; Küster B; Jung A
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):669-682. PubMed ID: 36401637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer.
    Song W; Ma Y; Wang J; Brantley-Sieders D; Chen J
    Cancer Res; 2014 May; 74(9):2444-54. PubMed ID: 24607842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoproteomics-Aided Medicinal Chemistry for the Discovery of EPHA2 Inhibitors.
    Heinzlmeir S; Lohse J; Treiber T; Kudlinzki D; Linhard V; Gande SL; Sreeramulu S; Saxena K; Liu X; Wilhelm M; Schwalbe H; Kuster B; Médard G
    ChemMedChem; 2017 Jun; 12(12):999-1011. PubMed ID: 28544567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemical Proteomics and Structural Biology Define EPHA2 Inhibition by Clinical Kinase Drugs.
    Heinzlmeir S; Kudlinzki D; Sreeramulu S; Klaeger S; Gande SL; Linhard V; Wilhelm M; Qiao H; Helm D; Ruprecht B; Saxena K; Médard G; Schwalbe H; Kuster B
    ACS Chem Biol; 2016 Dec; 11(12):3400-3411. PubMed ID: 27768280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.